All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs offers cutting-edge allogeneic CRISPR hybrid RNA-DNA gene editing chimeric antigen receptor T (CAR-T) cell development service, allowing for precise and efficient genetic modification of immune cells for therapeutic applications. By harnessing the power of CRISPR technology, we tailor CAR-T cells to target specific antigens, enhancing their efficacy and reducing off-target effects. Our team of experts specializes in the development of allogeneic CAR-T cell therapies, offering a comprehensive and customizable approach to gene editing that meets the unique needs of our clients.
CRISPR hybrid RNA-DNA gene editing is a cutting-edge technology that combines the precision of CRISPR-Cas9 gene editing with the versatility of RNA-guided editing. In this approach, a synthetic guide RNA molecule is designed to target a specific gene sequence in the DNA, allowing the Cas9 protein to make precise cuts and edits to the gene. One of the key advantages of CRISPR hybrid RNA-DNA gene editing is its ability to target specific sequences within the genome with high precision, allowing for more accurate and efficient gene editing.
Fig.1 Applications of CRISPR technology on CAR-T cells.1
Creative Biolabs offers the allogeneic CRISPR hybrid RNA-DNA gene editing CAR-T cell development service which combines cutting-edge gene editing technology with the powerful immune cell therapy approach of CAR-T cells. With our service, we can modify T cells using a combination of CRISPR gene editing tools, including both RNA and DNA-based approaches, to precisely target and edit specific genes of interest. This enables the creation of engineered CAR-T cells with enhanced therapeutic properties, such as improved targeting of tumor cells and increased persistence and efficacy in the body.
The workflow for the Allogeneic CRISPR Hybridization RNA-DNA Gene Editing CAR-T Cell Development Service begins with sample collection, followed by isolation and manipulation of T cells to express CARs. Next, allogeneic CRISPR hybrid RNA-DNA gene editing technology was used to precisely edit and modify T cells to enhance their anti-tumor activity. The edited CAR-T cells are then expanded in culture to reach therapeutic doses, and then subjected to rigorous quality control testing to ensure safety and efficacy.
If you are interested in exploring the cutting-edge technology of Allogeneic CRISPR Hybrid RNA-DNA Gene Editing CAR-T Cell Development, we invite you to contact us now to learn more about our innovative services. Our team of experts is dedicated to providing you with top-notch service and support throughout the entire process. Whether you have questions or are ready to get started on your project, we are here to help. Reach out to us now to begin your journey toward innovative and cutting-edge cell development solutions.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION